Connect with us

BUSINESS

Revive Therapeutics Ltd (OTCMKTS: RVVTF) Submits Orphan Drug Application For Bucillamine For IRI Prevention During Liver Transplant

Published

on

Revive Therapeutics Ltd (OTCMKTS: RVVTF) has submitted an application to the US FDA for an Orphan Drug Designation for Bucillamine in ischemia-reperfusion injury (IRI)prevention during a liver transplant.

Ischemia-reperfusion injury doesn’t have any approved treatment 

There are no approved therapies for IRI currently. Ischemia-reperfusion damage is a common complication of liver transplantation and among the main causes of postoperative hepatic dysfunction, increasing morbidity and mortality risk. According to the United Network for Organ Sharing (“UNOS”), 8,906 liver transplants were performed in 2020, with 11,664 people on the liver transplant waiting list at the time of the ODD submission. Many therapeutic techniques have been found to be effective in controlled animal settings, but the majority have generated ambiguous outcomes in clinical practice or are yet to enter human clinical trials.

CEO Michael Frank commented, “We are continuing to advance novel uses of Bucillamine not only as a treatment for infectious diseases, but also for rare conditions that have no treatment options such as IRI. The FDA orphan drug application for Bucillamine as a potential solution in preventing IRI during liver transplantation and subsequently to other organ transplants complements our overall strategy of developing Bucillamine as a strong platform for other conditions.”

Bucillamine has the potential of reducing anti-inflammatory effects during transplant 

According to Revive, Bucillamine usage during liver transplantation has the potential to be a safe and effective way to meet the unmet medical need for a proprietary method to restrict or avoid IRI. Notably, Bucillamine is a cysteine derivative with two donatable thiol groups and can refill the thiol group in glutathione, reactivating the endogenous defense against oxidant harm in the context of IRI. Also, Bucillamine appears to have anti-inflammatory properties unrelated to the antioxidant properties.

The company believes Bucillamine has the potential to solve the shortage of high-quality organs by making steatotic livers less susceptible to IRI and hence more available for transplantation. Most importantly, Bucillamine has the potential to improve graft function and patient outcomes by lessening or preventing IRI during surgery and liver transplantation.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

BUSINESS

Medipharm Labs Corp (OTCMKTS: MEDIF) Completes Payment Of Its 2020 Convertible Debt Of $41 Million

Published

on

Medipharm Labs Corp (OTCMKTS: MEDIF) has announced that it has finalized all payments necessary under its 2020 unsecured convertible debt of $41 million. 

Medipharm pays off the convertible debt in the path towards profitability 

CEO MediPharm Labs Bryan Howcroft said, “MediPharm continues on its plan and path to profitability, and paying off our convertible debt in full is a major milestone on that path. Being essentially debt free with a strong cash position adds even more longevity to our business. As part of our growing nascent industry, this advantageous position differentiates us from some of our peers who may not have the runway to realize the industry’s full potential.”

The company executed a $37.8 million private placement with a US institutional investor on June 8, 2020, via the issuing of 2 senior unsecured convertible notes. The notes began to be amortized in October 2020, with bi-monthly installment payments due on the 1st and 10th business days of every month before the maturity period of June 8, 2023, in cash or shares. 

The note holder had the alternative of converting accelerated installment amounts in part or in full at an installment price determined computed in line with the provisions of the notes during the time between payment dates. The total debt had already been serviced in full via cash payments and share excitations as of December 31, 2021. As a result, the debt is fully extinguished eighteen months ahead of the maturity date.

Medipharm doesn’t have any major debt, and its balance sheet is clean 

MediPharm has no additional major debt and full control of its assets, which comprises two GMP facilities in Ontario, Canada, and another in the state of Victoria in Australia. Production infrastructure and machinery are also significant assets.

The company is currently debt arrangement-free and has a clean balance sheet with a solid cash position. This position, along with a thorough plan to minimize overhead, operational expenditures, and general and administrative expenses, allows MediPharm sustainability to deliver on its pipeline and sales contracts. 

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Digital Asset Monetary Network Inc. (OTCMKTS: DATI) Partners To Acquire Top-Level-Domain .hiphop

Published

on

Digital Asset Monetary Network Inc. (OTCMKTS: DATI)  has announced that in collaboration with experienced domain Name sector executive-entrepreneurs, it has bought Top-Level-Domain .hiphop rights via Dot HipHop LLC, whose collaboration is listed in DAMN’s third-quarter 2021 financial disclosures. 

DAMN acquired .hiphop domain rights 

Initially, the company had made the disclosure without revealing the name of the Top-Level-Domain as .hiphop. The move was to protect the Internet Corporation for Assignment of Names and Numbers (ICANN) integrity. Interestingly, just like in the case with most gTLD assignments, the .hiphop gTLD Registry Agreement will be subject to ICANN authorization that might not be withheld arbitrarily.  

Dot HipHop acquired ICANN authorization to finalize the .hiphop TLD assignment from the former holder, and DAMN wanted to reveal the gTLD name after  Hip Hop had been given approval. Although this is yet to happen, Domain Incite has identified and revealed the relationship between DAMN and .hiphop. 

Ajene Watson, CEO of DigitalAMN, said, “We are truly excited about .hiphop for so many reasons. One being, that we get the opportunity to partner and work with several incredibly experienced, well known and highly respected figures in the domaining space. Another is… this is Hip Hop.”

Hip Hop culture brings awareness to inequalities and inequities 

Watson continued, “As a culture, Hip Hop has helped to break down barriers, bring awareness to inequities and inequalities, and give both the undervalued and unvoiced platforms to stand, grow and flourish. And of course, this venture gives us the opportunity to work with ‘thought leaders’, artists, entertainers, designers, business leaders and the Icons of Hip Hop. The .hiphop gTLD fits our mission to help everyday people establish and grow transferable wealth, through financial literacy and access to economic opportunities. We believe that our PAI Ecosystem, coupled with the exciting prospects the company should see due to the Dot Hip Hop venture, will truly be effective in achieving this goal in 2022.”

Despite ICANN approval taking longer, the company is not concerned with the delay and is working with industry veterans to rectify the issue. 

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Icanic Brands Company Inc. (OTCMKTS: ICNAF) offers updates regarding the management cease trade order filed on November 30, 2021

Published

on

Icanic Brands  Company Inc. (OTCMKTS: ICNAF) has offered an update regarding the status of the management cease trade order issued by the British Columbia Securities Commission on November 30, 2021, as per National Policy 12-203 – Management Cease Trade Order.

Icanic Brands filed a Management Cease Trade Order.

On November 30, 2021, the company revealed that the submission of financial statements for the fiscal year ending July 31, 2021, and accompanying management discussions and analysis would be delayed past the prescribed periods as per the Canadian securities laws because of various reasons. The company was expected to finalize the financial statements and accompanying management discussions and analysis by November 29, 2021, which is the date it was supposed to file the filings as per relevant Canadian securities law requirements. Additionally, because of the delay in filing the yearly financial statements, the preliminary financial statement and associated management discussions and analysis for the quarter ending October 31, 2021, have been postponed beyond the required timeframe. The delay in filing of audited financial accounts was due to COVID-19 related delays in receiving information associated with subsidiaries the company obtained during that fiscal period.

Icanic expects to file annual financial statements by January 29, 2022

The company expects to file the Annual and Interim Filings for the fiscal year ending October 31, 2021, on or by January 29, 2022. Icanic Brands will give additional timetable updates as needed.

The general investing community will be allowed to trade in Iconic Brands’ listed common shares during the MCTO. Interestingly, the company’s chief finance officer and chief executive officer, on the other hand, will be unable to trade in the stock.

Most importantly, there are no major amendments to the facts provided in the Default Announcement other than those revealed in this press release. However, for as long as the company is in default of the Annual Filings stipulation, the company acknowledges that it intends to comply with the provisions of NP 12- 203 and will continue to produce bi-weekly default progress reports.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories